4//SEC Filing
Jones Michael L 4
Accession 0001127602-20-030706
CIK 0000882796other
Filed
Dec 6, 7:00 PM ET
Accepted
Dec 7, 4:24 PM ET
Size
5.4 KB
Accession
0001127602-20-030706
Insider Transaction Report
Form 4
Jones Michael L
Exec. Director, Finance - PAO
Transactions
- Award
Emp. Stock Option (Right to Buy)
2020-12-03+5,000→ 5,000 totalExercise: $5.45From: 2020-12-03Exp: 2023-08-08→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001800060
Filing Metadata
- Form type
- 4
- Filed
- Dec 6, 7:00 PM ET
- Accepted
- Dec 7, 4:24 PM ET
- Size
- 5.4 KB